Applied Genetic Technologies Corporation

Equities

AGTC

US03820J1007

Biotechnology & Medical Research

Applied Genetic Technologies Corporation Announces Resignation of R. Guyer from the Board

December 16, 2017 at 02:46 am IST

On December 12, 2017, Applied Genetic Technologies Corporation announced that David R. Guyer, M.D. resigning from the board of directors effective immediately. Dr. Guyer’s decision to resign from board of directors was not the result of any disagreement on any matter related to operations, policies or practices.

Latest news about Applied Genetic Technologies Corporation

Syncona's Achilles says cancer treatment shows promise; seals buy	01/22/01	AN
British Investor Syncona Closes Acquisition of US Biotech Applied Genetic Technologies	01/22/01	MT
Applied Genetic Technologies Corporation(NasdaqGM:AGTC) dropped from NASDAQ Composite Index	01/22/01	CI
Syncona Limited, a fund managed by Syncona Investment Management Limited completed the acquisition of Applied Genetic Technologies Corporation.	30/22/30	CI
Applied Genetic Technologies Says Syncona Extends Tender Offer Through Wednesday	29/22/29	MT
TOP NEWS: AstraZeneca to buy Neogene for cancer treatment	29/22/29	AN
Syncona Extends Offer Period For $24 Million Takeover of Applied Genetic Technologies	29/22/29	MT
Applied Genetic Technologies Corporation(NasdaqGM:AGTC) dropped from S&P TMI Index	29/22/29	CI
North American Morning Briefing : Stock Gains Seen -2-	22/22/22	DJ
Applied Genetic Technologies Corporation Reports Earnings Results for the First Quarter Ended September 30, 2022	22/22/22	CI
North American Morning Briefing : Positive China -2-	15/22/15	DJ
Wells Fargo Trims Applied Genetic Technologies' Price Target to $0.40 From $0.50, Keeps Equalweight Rating	25/22/25	MT
HC Wainwright Downgrades Applied Genetic Technologies to Neutral From Buy	25/22/25	MT
Chardan Research Downgrades Applied Genetic Technologies to Neutral From Buy, Adjusts Price Target to $0.34 From $3	25/22/25	MT
Sector Update: Health Care Stocks Pacing Monday Markets as Defensive Sectors Shine	25/22/25	MT
Sector Update: Health Care Stocks Pacing Monday Markets Advance	24/22/24	MT
Applied Genetic Technologies Shares Soar After Company Agrees to Sell to Syncona for $23.5 Million	24/22/24	MT
Stifel Nicolaus Downgrades Applied Genetic Technologies to Hold From Buy, Adjusts Price Target to $0.34 From $3	24/22/24	MT
Wall Street Set to Open Higher as Markets Look to Build on Strong Week Ahead of PMI Data	24/22/24	MT
ETF Preview: ETFs, Futures Rising Pre-Bell After Chicago Fed National Activity Index Report	24/22/24	MT
Wedbush Downgrades Applied Genetic Technologies to Neutral From Outperform, Adjusts Price Target to $0.34 From $2 on Syncona Tender Offer	24/22/24	MT
US Futures Higher, Looking to Build on Strong Week Ahead of PMI Data	24/22/24	MT
Top Premarket Gainers	24/22/24	MT
Transcript : Applied Genetic Technologies Corporation, Syncona Limited - M&A Call	24/22/24
Applied Genetic Technologies Agrees to Sell to Syncona for $23.5 Million Through Tender Offer	24/22/24	MT

Chart Applied Genetic Technologies Corporation

Duration

Period

Chart Applied Genetic Technologies Corporation

More charts

Company Profile

Applied Genetic Technologies Corporation is a clinical-stage biotechnology company. The Company uses gene therapy platform to develop genetic therapies for patients suffering from rare and debilitating diseases. Its focus is on the field of ophthalmology where it has active clinical programs in X-linked retinitis pigmentosa (XLRP), achromatopsia (ACHM) and a optogenetics program, as well as a preclinical program in dry age-related macular degeneration (dAMD). It has approximately one preclinical program in otology and two preclinical programs targeting central nervous system disorders (CN), including frontotemporal dementia and amyotrophic lateral sclerosis. Its optogenetics program is being developed in collaboration with Bionic Sight, LLC and its otology program is being developed in collaboration with Otonomy, Inc. In addition to its product pipeline, the Company has also developed broad technological and manufacturing capabilities in synthetic promoter development and optimization.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	+16.73%	123B
REGENERON PHARMACEUTICALS, INC.	+13.04%	107B
BIONTECH SE	-5.80%	24.01B
ARGENX SE	+1.69%	22.59B
GENMAB A/S	-10.09%	18.16B
WUXI APPTEC CO., LTD.	-40.52%	16.84B
BEIGENE, LTD.	-14.00%	16.23B
NEUROCRINE BIOSCIENCES, INC.	+1.18%	13.43B
SAREPTA THERAPEUTICS, INC.	+24.18%	11.32B

Bio Therapeutic Drugs